KKH and the National Skin Centre say there are more such patients, but no recent studies have been done. Read more at ...

The prevalence of eczema in Singapore has been largely stable in the past decade, affecting about one in five children and ...

No significant difference in the risk for MACE was observed between patients with IBD receiving JAK vs TNF inhibitors.

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, provided an update on clinical progress and ...

PhD Defense: Effectiveness and safety of dupilumab and JAK-inhibitors in daily practice; Optimizing Treatment for Atopic Dermatitis ...

Syntara hopes to emulate the success of Ojjaara, a $2.6 billion home-grown myelofibrosis therapy approved in the US.

The researchers found nearly half (47%) of the posts focused on efficacy, while 16% discussed adverse effects such as acne, ...

The 48-week end points of the MANIFEST-2 study show improvements in spleen reduction, symptoms, bone marrow fibrosis, and ...

TransThera Sciences Nanjing, Inc. (the 'TransThera') announced the poster presentation at the 2024 European Society For Medical Oncology (ESMO) Asia Congress to discuss the clinical study of ...

Secura Bio, Inc. ( ), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies, today announced Dr. Alison Moskowitz, ...

Filgotinib, a JAK1 preferential inhibitor, shows promise as an effective and well-tolerated maintenance therapy for Crohn's ...

Sumitomo Pharma America, Inc. (SMPA) today presented new clinical data supporting further development of nuvisertib, an investigational small molecule being researched for the treatment of ...